IL23A and inflammatory bowel disease: Our observations support the rationale for IL-23–targeted agents in patients with overlapping psoriasis and inflammatory bowel disease, and they provide exploratory evidence that the psoriasis-labeled regimen of GUS may suffice for selected UC patients.